EVOKE PHARMA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 8 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-04-27: Reporting owner WIDDER KENNETH J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-04-27: Reporting owner REED VICKIE S; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-04-27: Reporting owner Hill Malcolm R; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-04-27: Reporting owner GARNER CAM L; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-04-27 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +56,000 56,000 owned after | $0.66 exercise price | 2022-04-28 | |
| 2022-04-27 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,000 58,000 owned after | $0.66 exercise price | 2022-04-28 | |
| 2022-04-27 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,750 57,750 owned after | $0.66 exercise price | 2022-04-28 | |
| 2022-04-27 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +67,500 67,500 owned after | $0.66 exercise price | 2022-04-28 | |
| 2022-04-27 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +57,750 57,750 owned after | $0.66 exercise price | 2022-04-28 | |
| 2022-02-02 | Gonyer David A Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,000 175,000 owned after | $0.55 exercise price | 2022-02-04 | |
| 2022-02-02 | D'Onofrio Matthew J Officer (Exec VP, Chief Bus. Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.55 exercise price | 2022-02-04 | |
| 2022-02-02 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.55 exercise price | 2022-02-04 |